Use of mannanoligosacharides as an adjuvant treatment for gastrointestinal diseases and this effects on E.coli inactivated in dogs

• Autor(a) principal: Gouveia,Eliana Maria Ferreira
• Data de Publicação: 2006
• Outros Autores: Silva,Iandara Schettert, Van Onselem,Valter Joost, Corrêa,Rui Alberto Caetano, Silva,Camila Junqueira e
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Acta Cirúrgica Brasileira (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502006001000006
• topic: Gastroenteritis; Escherichia coli; Probiotics; Dog Diseases

PURPOSE: To evaluate the effects of mannanoligosacharides on dogs showing gastroenteritis. METHODS: Sixteen dogs, 2-6 month-old, distributed into two groups: T1 - animals with gastroenteritis receiving treatment for the disease + mannanoligosacharides (2 g/animal).; and T2 - animals with gastroenteritis receiving just treatment for the disease. The animals were randomly included in the sample and all of them were submitted to blood and feces collection for coproculture. In the treatment for gastroenteritis antibiotic, antihemetic, vermifuge, vitamins and sorotheraphy were used. The parameters evaluated were the numbers of leucocytes, neutrophils, lymphocytes and the presence of enteropathogenic bacteria in feces. RESULTS: The mannanoligosacharides was effective in eliminating pathogenic E. coli in 85.71% of the animals, while in the no-treated group only 25% of the animals were negative to E. coli. CONCLUSION: The mannanoligosacharides is effective in the control of pathogenic E. coli and it can be indicated as an adjuvant treatment for gastroenteritis in dogs.